Clinical Trials Browser

NCT03866382 2026-04-16

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT05616650 2026-04-16

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

Phase 2 Recruiting

42 enrolled

Genitourinary

Prostatic Neoplasms

NCT06347705 2026-04-16

A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer

Phase 2 Recruiting

57 enrolled

Genitourinary

Prostatic Neoplasms

NCT06991556 2026-04-16

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Phase 2 Recruiting

150 enrolled

Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT07110038 2026-04-16

DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma

Phase 2 Recruiting

25 enrolled

Genitourinary

Penile Squamous Cell Carcinoma (PSCC)

NCT07223424 2026-04-16

PSI-Immune

Phase 2 Recruiting

880 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Colitis, Ulcerative, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma

NCT03682289 2026-04-15

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Phase 2 Recruiting

89 enrolled

GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

NCT05155046 2026-04-15

18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy

Phase 2 Recruiting

130 enrolled

Genitourinary

Localized Prostate Cancer

NCT06161506 2026-04-15

Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer

Phase 2 Recruiting

41 enrolled

Genitourinary

Prostatic Hyperplasia, Prostatic Neoplasms, Urinary Incontinence, Urinary Incontinence, Stress, Urinary Incontinence, Urge

NCT06638931 2026-04-15

ANTARES

Phase 2 Recruiting

28 enrolled

BreastCNSEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETOther solid neoplasmSarcomaThoracic

Urachal adenocarcinoma, Urachal cancer, Fibrolamellar hepatocellular carcinoma, Secretory breast carcinoma, Carcinoma, Ovarian Epithelial, Adrenal Gland Neoplasms, Anus Neoplasms, Biliary Tract Neoplasms, Carcinosarcoma, Carcinoma, Adenoid Cystic, Fallopian Tube Neoplasms, Fibrosarcoma, Gallbladder Neoplasms, Granulosa Cell Tumor, Hemangiosarcoma, Leiomyosarcoma, Mesothelioma, Neuroblastoma, Parathyroid Neoplasms, Penile Neoplasms, Sarcoma, Sarcoma, Kaposi, Osteosarcoma, Thyroid Neoplasms, Trophoblastic Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Hepatoblastoma, Endodermal Sinus Tumor, Neuroectodermal Tumors, Primitive, Cholangiocarcinoma, Sertoli-Leydig Cell Tumor, Neurofibrosarcoma, Hemangioblastoma, Neuroendocrine Tumors

NCT06770582 2026-04-15

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Phase 2 Recruiting

160 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT07111507 2026-04-15

A Study of Tarlatamab for People With Prostate Cancer

Phase 2 Recruiting

32 enrolled

Genitourinary

Prostatic Neoplasms

NCT07237269 2026-04-15

Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer

Phase 2 Recruiting

140 enrolled

Genitourinary

Prostatic Neoplasms

NCT07475806 2026-04-15

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Phase 2 Recruiting

240 enrolled

Genitourinary

Muscle-invasive Bladder Cancer

NCT06053658 2026-04-14

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

Phase 2 Recruiting

48 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT06161532 2026-04-14

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

Phase 2 Recruiting

60 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT02960022 2026-04-13

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Phase 2 Recruiting

900 enrolled

Genitourinary

Prostatic Neoplasms

NCT04337580 2026-04-13

FASN

Phase 2 Recruiting

50 enrolled

Genitourinary

Neoplasms, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT04550494 2026-04-13

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Phase 2 Recruiting

36 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT05239624 2026-04-13

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

Phase 2 Recruiting

23 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT05691465 2026-04-13

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Phase 2 Recruiting

30 enrolled

Genitourinary

Prostatic Neoplasms

NCT05969496 2026-04-13

NEOPAX

Phase 2 Recruiting

17 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT06022822 2026-04-13

Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial

Phase 2 Recruiting

90 enrolled

Genitourinary

Prostate Adenocarcinoma

NCT06388720 2026-04-13

IMGeS

Phase 2 Recruiting

82 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06594926 2026-04-13

WOMBAT

Phase 2 Recruiting

69 enrolled

Genitourinary

Prostatic Neoplasms

NCT06610825 2026-04-13

CaRPET

Phase 2 Recruiting

60 enrolled

Genitourinary

Prostatic Neoplasms

NCT07061964 2026-04-13

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Phase 2 Recruiting

111 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT07220720 2026-04-13

POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2/3 Lesions

Phase 2 Recruiting

30 enrolled

Genitourinary

Prostatic Neoplasms

NCT05048212 2026-04-09

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

Phase 2 Recruiting

20 enrolled

CNSGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell

NCT06695845 2026-04-09

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Phase 2 Recruiting

200 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06995677 2026-04-09

SURF302

Phase 2 Recruiting

90 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT05327686 2026-04-08

SAMURAI

Phase 2 Recruiting

240 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT05457699 2026-04-08

ANCHORProstate

Phase 2 Recruiting

80 enrolled

Genitourinary

Prostate Cancer Metastatic

NCT06503614 2026-04-08

ENHANCE

Phase 2 Recruiting

60 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06567743 2026-04-08

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Phase 2 Recruiting

325 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06760819 2026-04-08

panSOHO

Phase 2 Recruiting

111 enrolled

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors

NCT07287150 2026-04-08